• TSA Multi-colour Immunofluorescence: Evidence Scope

  2026-10-15

  The APExBIO Tyramide Signal Amplification (TSA) Multi-colour Immunofluorescence System Kit (4-Color), SKU K4310, is described as an HRP-dependent fluorescence-amplification product for immunofluorescence, immunohistochemistry, immunocytochemistry and in situ hybridization. Its stated measurement principle is localized covalent deposition of fluorescent tyramide near an HRP-labeled detection complex. The available evidence is limited to product information: the reported approximately 100-fold sensitivity increase, rapid labeling claim, multiplex scope and sequential-labeling compatibility have not been independently assessed here against a matched research study or comparator.

• Amyloid Beta-Peptide (1-40): Scope and Evidence

  2026-10-15

  APExBIO describes Amyloid Beta-Peptide (1-40) (human), SKU A1124, as a synthetic 40-residue human Aβ peptide intended for Alzheimer’s disease research contexts. The available product description supports identity, biological context, and broad measurement roles, but it does not provide an identity-matched study, quantitative outcomes, or independent evidence of product-specific performance.

• (Z)-4-Hydroxytamoxifen: Evidence and Scope

  2026-10-14

  APExBIO describes (Z)-4-hydroxytamoxifen, SKU B5421, as the Z isomer and active metabolite of tamoxifen, with competitive estrogen-receptor activity and reported antiestrogenic effects in prolactin and immature-rat uterine readouts. Because no identity-matched research paper, assay details, sample sizes, uncertainty estimates, or independent replication are available here, these claims should be treated as supplier-documented evidence rather than a complete research literature base.

• Q-VD-OPh in Apoptosis and Mitophagy Research

  2026-10-14

  Q-VD-OPh is described by APExBIO as a cell-permeable pan-caspase inhibitor for probing caspase-dependent cell death. Its conceptual value lies in separating caspase activity inhibition from upstream mitochondrial quality-control events. The supplied Rab14 study supports a role for Rab14 in Parkin-dependent mitophagy, but it does not establish that Q-VD-OPh was used or that caspase inhibition explains the reported phenotype.

• tRNA Self-Supply in Cell-Free Translation

  2026-10-13

  A 2025 Nature Communications study reports continuous in situ production of a complete 21-tRNA set in a PURE cell-free system, supporting sustained protein expression for up to 20 hours. The result advances biochemical self-regeneration conceptually, but it does not demonstrate a fully self-regenerating synthetic cell or establish clinical, cellular, or product-specific applicability.

• Monomeric Aβ and Microglia in Brain Development

  2026-10-13

  Kwon and colleagues report that monomeric amyloid-β can signal through an APP- and Ric8a-dependent pathway in microglia, influencing cortical development in mice. The findings expand discussion of amyloid-β beyond plaque-associated toxicity, but the evidence remains limited by unresolved molecular relationships, developmental context, and the absence of human or clinical data.

• Native PAGE Principles and Cancer Biology Evidence

  2026-10-12

  Native protein gel electrophoresis can preserve some protein complexes and activities, but its separation patterns are governed by charge, size, shape, and interactions rather than isoelectric point alone. The cited Dinaciclib study provides preclinical evidence in VHL-deficient clear cell renal cell carcinoma models; it does not validate the APExBIO kit or establish clinical efficacy.

• 1-methyl Adenosine: Evidence and Limits

  2026-10-12

  A source-grounded overview of 1-methyl Adenosine (1-methyl Ado), emphasizing what a 2024 analytical chemistry study demonstrates about measurement and what it does not establish about disease biology, diagnosis, or treatment.

• Epalrestat and Parkinson’s Disease: Evidence Limits

  2026-10-11

  A preclinical study links Epalrestat to KEAP1/Nrf2 signaling, reduced oxidative stress, and dopaminergic-neuron protection in cellular and mouse Parkinson’s disease models. The findings are mechanistically suggestive but do not establish clinical efficacy, disease modification, or safety in people.

• Rapamycin (Sirolimus): mTOR Evidence Guide

  2026-10-10

  Rapamycin, also called Sirolimus, is an FKBP12-dependent inhibitor used to interrogate mTOR signaling. Evidence supports its value in immunology, cancer biology, mitochondrial disease models, and pathway-focused cell studies, but potency and phenotype claims remain assay- and model-dependent.

• Vasopressin Analogues: Mechanisms and Evidence

  2026-10-09

  The 2022 review by Glavaš and colleagues explains how vasopressin receptor biology, peptide structure, and pharmacokinetics shape the distinct profiles of lypressin, desmopressin, terlipressin, and related analogues. Its main practical contribution is an integrated framework for interpreting antidiuretic, vasoconstrictive, hemostatic, and emerging antiviral claims while distinguishing established therapeutic evidence from early-stage hypotheses.

• How Calcium Shapes Aβ Aggregation at Membranes

  2026-10-09

  A 2024 PCCP study used supercritical angle Raman and fluorescence approaches to examine how calcium ions influence amyloid-beta aggregation at lipid interfaces. Its findings suggest that a calcium-rich interfacial layer can reduce membrane-associated peptide insertion, with a stronger sequence-dependent effect for Aβ1–42 than for Aβ1–40.

• Entecavir: Evidence, Mechanism, and HBV Translation

  2026-10-08

  Entecavir, also known as BMS200475, is examined through its HBV polymerase mechanism, resistance profile, and translational evidence. This article adds an evidence-calibration framework that separates cell-based potency, animal findings, and clinically meaningful chronic hepatitis B outcomes.

• O-GlcNAc–HUWE1–TfR1 Axis in Preeclampsia

  2026-10-08

  The reference study identifies an O-GlcNAc–HUWE1–TfR1 pathway linking protein modification, iron uptake, ferroptosis, and trophoblast syncytialization in preeclampsia. Its combined placental, cellular, proteomic, and mouse evidence supports a mechanistic model, while important questions remain about human applicability, pathway selectivity, and therapeutic translation.

• Nystatin as a Mechanistic Control in Cell Entry Studies

  2026-10-07

  Nystatin (Fungicidin) is best known for ergosterol-dependent antifungal activity, but a 2019 study used it to interpret membrane-associated entry of Spiroplasma eriocheiris into Drosophila S2 cells. This article explains why the negative result matters, what it can support, and where its interpretation must stop.

8107 records 1/541 page Next 12345 下5页 Last page